News Releases:


miRagen Therapeutics Named to FierceBiotech’s 2012 Fierce 15 List of Most Promising Private Biotechnology Companies

Boulder, Colorado, September 19, 2012 – FierceBiotech today named miRagen Therapeutics as one of 2012’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech’s tenth annual Fierce 15 selection.... View »

miRagen Therapeutics Announces the Publication of Compelling Data Suggesting the MIRG-9103 Program May Have Utility in Treating Multiple Disorders Associated with Metabolic Syndrome

Research reveals the heart’s role in controlling systemic energy balance and suggests miRagen’s lead program may have broad cardiometabolic benefit Study results published today in the prestigious scientific journal Cell BOULDER, CO, April 26, 2012 – MiRagen Therapeutics, Inc.,... View »

miRagen Therapeutics Secures $20 Million Series B Financing

Proceeds to advance miRagen’s microRNA-based therapeutics pipeline New investor Remeditex Ventures leads the round joining all existing investors BOULDER, CO, April 24, 2012 – MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment... View »

miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran

Dr. Arthur A. Levin Joins as Executive Vice President of Research and Development Dr. Levin, a world expert on the preclinical and clinical development of oligonucleotide-based therapeutics, to serve as miRagen’s head of R&D. As leader of the project... View »

miRagen Therapeutics to Present at Biotech Showcase 2012

BOULDER, CO, January 5, 2012 – MiRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that William S. Marshall, Ph.D., President and Chief Executive... View »